Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 6.00%
As of Tuesday, October 20, X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 6.00%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.60%
As of Monday, October 19, X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 5.60%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.92%
As of Thursday, October 15, X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 5.92%, which has investors questioning if this is right time to sell.Michael Rose
Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Down 7.89%
As of Wednesday, September 23, X4 Pharmaceuticals, Inc.’s XFOR share price has dipped by 7.89%, which has investors questioning if this is right time to buy.Michael Rose
Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Down 5.80%
As of Tuesday, September 15, X4 Pharmaceuticals, Inc.’s XFOR share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $300.4 | $228.4 | 32% |
|
| Shares Out (Mil) | 126.3 | 53.9 | 67% |
|
| Institutional Ownership | 98.9% | 92.9% | 83% |
|
| Float (Mil) | 57.2 | 41.7 | 50% |
|
| Beta | 0.39 | 0.95 | 22% |
|
| Avg Daily Volume (000s) | 608 | 582 | 62% |
|
| Price Change (52-week) |
2.0% | 47.6% | 53% |
|
| Growth | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 63.5% | 13.6% | 97% |
|
| Net Income (5yr) | (5.0%) | (10.1%) | 34% |
|
| EPS (5yr) | 54.2% | 15.8% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.5% | (15.7%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 4 | |
| Current EPS | ($0.186) | ($0.668) | ($0.768) | |
| Month Ago EPS | ($0.186) | ($0.668) | ($0.768) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.192) | ($0.730) | ($0.820) | |
| Year/Year Chg | 43.1% | (64.3%) | (53.4%) | |
| Financials | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $16 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($90) | ($44) | 12% |
|
| EPS (TTM) | ($0.885) | ($1.500) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($84) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $156 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $77 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $329 | $177 | 30% |
|
| Valuation | XFOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.87 | 2.19 | 51% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.5% | 66.9% | 89% |
|
| Net Margin | (568.8%) | (73.7%) | 1% |
|
| ROA | (50.3%) | (47.1%) | 11% |
|
| ROE | (113.1%) | (54.1%) | 8% |
|
| Liabilities to Assets | 38.6% | 29.1% | 29% |
|
| F-Score | 3 | 2 | 18% |
|
X4 Pharmaceuticals, Inc. did not pass any screens on 10/20/2026.
